SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalNNVC - NanoViricides, Inc.


Previous 10 Next 10 
From: Dr.Leonardo7/27/2005 8:02:55 PM
   of 12865
 
Notice a lead story in Yahoo today...sounds familiar? Look at the companys website www.nanoviricides.com

news.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Dr.Leonardo who wrote (37)7/28/2005 8:42:10 AM
From: donpat
   of 12865
 
Yes, indeed - I was just going to post the same story (different source)!

Here's mine:

MIT Engineers An Anti-Cancer Smart Bomb


Cambridge MA (SPX) Jul 28, 2005
Imagine a cancer drug that can burrow into a tumor, seal the exits and detonate a lethal dose of anti-cancer toxins, all while leaving healthy cells unscathed.
MIT researchers have designed a nanoparticle to do just that.

The dual-chamber, double-acting, drug-packing "nanocell" proved effective and safe, with prolonged survival, against two distinct forms of cancers--melanoma and Lewis lung cancer--in mice.

The work will be reported in the July 28 issue of Nature, with an accompanying commentary.

"We brought together three elements: cancer biology, pharmacology and engineering," said Ram Sasisekharan, a professor in MIT's Biological Engineering Division and leader of the research team.

"The fundamental challenges in cancer chemotherapy are its toxicity to healthy cells and drug resistance by cancer cells," Sasisekharan said. "So cancer researchers were excited about anti-angiogenesis," the theory that cutting off the blood supply can starve tumors to death. That strategy can backfire, however, because it also starves tumor cells of oxygen, prompting them to create new blood vessels and instigate metastasis and other self-survival activities.

The next obvious solution would be combining chemotherapy and anti-angiogenesis--dropping the bombs while cutting the supply lines. But combination therapy confronted an inherent engineering problem. "You can't deliver chemotherapy to tumors if you have destroyed the vessels that take it there," Sasisekharan said. Also, the two drugs behave differently and are delivered on different schedules: anti-angiogenics over a prolonged period and chemotherapy in cycles.

"We designed the nanocell keeping these practical problems in mind," he said. Using ready-made drugs and materials, "we created a balloon within a balloon, resembling an actual cell," explains Shiladitya Sengupta, a postdoctoral associate in Sasisekharan's laboratory.

In addition to Sasisekharan and Sengupta, the co-authors are David Eavarone, Ishan Capila and Ganlin Zhao of MIT's Biological Engineering Division; Nicki Watson of the Whitehead Institute for Biomedical Research; and Tanyel Kiziltepe of MIT's Department of Chemistry.

The team loaded the outer membrane of the nanocell with an anti-angiogenic drug and the inner balloon with chemotherapy agents. A "stealth" surface chemistry allows the nanocells to evade the immune system, while their size (200 nanometers) makes them preferentially taken into the tumor. They are small enough to pass through tumor vessels, but too large for the pores of normal vessels.

Once the nanocell is inside the tumor, its outer membrane disintegrates, rapidly deploying the anti-angiogenic drug. The blood vessels feeding the tumor then collapse, trapping the loaded nanoparticle in the tumor, where it slowly releases the chemotherapy.

The team tested this model in mice. The double-loaded nanocell shrank the tumor, stopped angiogenesis and avoided systemic toxicity much better than other treatment and delivery variations.

But it is patient survival and quality of life that really inspire this research, Sasisekharan said. Eighty percent of the nanocell mice survived beyond 65 days, while mice treated with the best current therapy survived 30 days. Untreated animals died at 20.

"It's an elegant technique for attacking the two compartments of a tumor, its vascular system and the cancer cells," said Judah Folkman of Children's Hospital Boston. "This is a very neat approach to drug delivery," said MIT Institute Professor Robert Langer.

The nanocell worked better against melanoma than lung cancer, indicating the need to tweak the design for different cancers. "This model enables us to rationally and systematically evaluate drug combinations and loading mechanisms," says Sasisekharan. "It's not going to stop here. We want to build on this concept."

spacedaily.com

Nano certainly is doing wonderful, amazing, things and will be the saviour of us all, eventually.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (38)7/28/2005 7:37:38 PM
From: jmhollen
   of 12865
 
Hi guys,

Please note that if heps to post a link on PRs and News here to the Under 0.25 and Radne's Boards, since a lot of SI'rs may not have NNVC "..SubjectMarked.." yet...:
Message 21552338

I already took care of it for you this time......................

Check you mail box for appropriate and handy links.

John :-)
.

Share RecommendKeepReplyMark as Last Read


From: donpat8/2/2005 9:43:39 AM
   of 12865
 
Nanotube-Laser Combo Selectively Targets Cancer Cells, Study Shows

[Another indication of the power in nano bio and its potential for mankind.]

SCIENCE NEWS
August 02, 2005

Carbon nanotubes--tiny straws of pure carbon--have many properties that make them attractive for applications as varied as nanoelectronics and nanofibers. Scientists are recruiting carbon nanotubes in the fight against cancer, too. A report published online this week by the Proceedings of the National Academy of Sciences suggests that when paired with a modified laser beam, the rods can act as tiny heaters to selectively destroy tumor cells.
When exposed to near-infrared light, carbon nanotubes quickly release excess energy as heat. Nadine Wong Shi Kam and her colleagues at Stanford University exploited this property to attack cancerous cells. "One of the longstanding problems in medicine is how to cure cancer without harming normal body tissue," notes study co-author Hongjie Dai. Cancer cells tend to be coated in folate receptors, whereas normal cells are not. Thus to ensure that the carbon nanotubes were attracted only to diseased cells, the researchers coated them with folate molecules. The team then shined a flashlight-size near-infrared laser on aqueous solutions of both tumor and normal cells. Although harmless to regular cells, the light heated the nanotubes to 70 degrees Celsius within two minutes, killing the cancer cells they had invaded.

The researchers hope to refine the process for future use. "Folate is just an experimental model that we used," Dai says. "In reality there are more interesting ways we can do this. For example, we can attach an antibody to a carbon nanotube to target a particular type of cancer." To that end, Dai is currently investigating the possibility of using the technique on mice with lymphoma because lymphoma cells have well-defined surface receptors that can be targeted. --Sarah Graham
sciam.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: jmhollen8/2/2005 1:29:11 PM
   of 12865
 
PLEASE NOTE: The quotes screw-up on mafia.com is a MegaOpportunity for everyone, IMHO.

I also expect that we will see RTQs & Level-II for NNVC in the immediate future.

My 'reco' would be "..collect and hold.."!!!

John :-)
.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (41)8/2/2005 2:10:44 PM
From: canbballtrader
   of 12865
 
What is mafia.com? Is there anywhere else to get good quotes since the pink sheets don't work for NNVC? Big drop today on no news. I agree about adding more.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: canbballtrader who wrote (42)8/2/2005 2:44:30 PM
From: jmhollen
   of 12865
 
Subject 55842

mafia.ocm = pinksheets.com. Less keystrokes, and it makes fun of the 'Streeter Stock' Snobs around here.....

NNVC is in the middle of their go-to-OTCBB audit, and blew off updating Pinksheets, so Pinksheets retaliated (..bunch of azzholes..) by stopping their quotes with no warning.

Free RealTime.com will give you Time & Sales on NNVC (..paying for FRT Express is recommended..), and you can interpolate from that. I just bought 30K at 0.018.

John :-)
.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (43)8/2/2005 4:48:14 PM
From: rrufff
   of 12865
 
Any info on capital structure? Can't find anything on this one........

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: rrufff who wrote (44)8/2/2005 5:24:53 PM
From: jmhollen
   of 12865
 
They're flying under the radar, doing the audit, and getting new products ready for launch.... ..Sounds like we'll get hit with a barrage next month....

Buy while the mafia.com quotes are hosed, when they're back (..with RTQs and L-II, I hope..) it should rebound quickly...

John :-)
.

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/3/2005 12:48:43 PM
   of 12865
 
"..Wheeeeeeeeeeeeeeeeeeeeeeeeee.......... ..I snagged another 10K for $0.175 during the noon sale...........

This is going to be fun when they get the mafia.com quotes fixed....

John :-)
.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10